Testosterone

ID: testosterone

Aliases: testosterone cypionate, testosterone enanthate, testosterone undecanoate, testosterone gel, Test C, TRT

Type: compound

Route/form: IM/subQ injection, transdermal, oral, buccal, nasal, or implant depending product; testosterone cypionate label is IM

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human, review/regulatory

Source types: human_rct, label, review, safety_review

Linked sources: 7

Broad outcomes: Fat loss / metabolic health, Hormones / fertility / sexual health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• androgen receptor agonist
• HPG-axis suppression via negative feedback
• estradiol conversion via aromatase
• DHT conversion via 5-alpha-reductase

Optimization domains

• androgen therapy
• testosterone
• muscle
• body composition
• endocrine
• fertility
• steroid

Research basis

• Approved testosterone products anchor replacement therapy for clearly defined hypogonadism, with route-specific label context and TRAVERSE providing large cardiovascular-safety data in appropriately selected hypogonadal men.
• The performance/body-composition signal is real: randomized human trials show supraphysiologic and graded testosterone exposure can increase fat-free mass, muscle size, strength/power, hemoglobin, and IGF-1 while changing HDL.
• It is the reference compound for judging SARMs, AAS, hCG, and SERMs because exogenous testosterone directly raises androgen exposure while suppressing endogenous LH/FSH signaling.

Limits, risks, and missing evidence

• Replacement therapy, high-normal TRT, and supraphysiologic cycling are different claims; TRAVERSE does not make bodybuilding-dose use cardiovascularly safe.
• HPG-axis suppression, infertility/testicular atrophy, erythrocytosis, estradiol/DHT conversion, acne/hair loss, gynecomastia, blood-pressure/lipid effects, sleep apnea, and cardiac/prostate monitoring dominate nonmedical risk framing.
• Serum testosterone, intratesticular testosterone, fertility, symptoms, hematocrit, estradiol, and performance are separate endpoints; keeping one in range does not guarantee the others are fine.

Risk flags

• prescription only
• endocrine suppression
• fertility risk
• erythrocytosis
• cardiovascular monitoring
• medical supervision

Linked papers, labels, and reviews

1. DailyMed label: Testosterone cypionate injection
   label / dailymed_testosterone_cypionate_label
   Official injectable testosterone label; anchors approved hypogonadism context, IM route, contraindications, and androgen adverse effects.
2. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
   human_rct / pubmed_testosterone_supraphysiologic_muscle_1996
   Landmark randomized human trial showing dose/exposure-linked muscle-size and strength effects; not a safety endorsement.
3. Effects of Testosterone Treatment in Older Men
   human_rct / pubmed_testosterone_trials_older_men_2016
   Coordinated Testosterone Trials source for older hypogonadal men; supports indication-specific benefits and endpoint-specific limits.
4. Anabolic-androgenic steroids: How do they work and what are the risks?
   review / pubmed_aas_risks_2023
   General AAS mechanism and risk review; used as class-level caution for nonmedical androgen/anabolic steroid entries.
5. Cardiovascular Safety of Testosterone-Replacement Therapy
   human_rct / pubmed_testosterone_traverse_cv_2023
   TRAVERSE cardiovascular-safety trial in symptomatic hypogonadal men with pre-existing or high cardiovascular risk; replacement-therapy context, not supraphysiologic cycling.
6. Testosterone dose-response relationships in healthy young men
   human_rct / pubmed_testosterone_dose_response_2001
   Graded testosterone-enanthate dosing under GnRH-agonist suppression; dose-dependent fat-free mass, muscle size, strength/power, hemoglobin, HDL, and IGF-1 effects.
7. Anabolic-androgenic steroids among recreational athletes and cardiovascular risk
   safety_review / pubmed_aas_recreational_athletes_cv_review_2025
   Recent cardiovascular-risk review focused on recreational athlete AAS use; class-level safety source for nonmedical androgen entries.